Literature DB >> 21135261

Higher fecal immunochemical test cutoff levels: lower positivity rates but still acceptable detection rates for early-stage colorectal cancers.

Jochim S Terhaar sive Droste1, Frank A Oort, René W M van der Hulst, Henk A van Heukelem, Ruud J L F Loffeld, Sietze T van Turenhout, Ilhame Ben Larbi, Shannon L Kanis, Maarten Neerincx, Mirre Räkers, Veerle M H Coupé, Anneke A Bouman, Gerrit A Meijer, Chris J J Mulder.   

Abstract

BACKGROUND: Adjusting the threshold for positivity of quantitative fecal immunochemical tests (FIT) allows for controlling the number of follow-up colonoscopies in a screening program. However, it is unknown to what extent higher cutoff levels affect detection rates of screen-relevant neoplasia. This study aimed to assess the effect of higher cutoff levels of a quantitative FIT on test positivity rate and detection rate of early-stage colorectal cancers (CRC).
METHODS: Subjects above 40 years old scheduled for colonoscopy in 5 hospitals were asked to sample a single FIT (OC sensor) before colonoscopy. Screen-relevant neoplasia were defined as advanced adenoma or early-stage cancer (stage I and II). Positivity rate, sensitivity, and specificity were evaluated at increasing cutoff levels of 50 to 200 ng/mL.
RESULTS: In 2,145 individuals who underwent total colonoscopy, 79 patients were diagnosed with CRC, 38 of which were with early-stage disease. Advanced adenomas were found in 236 patients. When varying cutoff levels from ≥ 50 to ≥ 200 ng/mL, positivity rates ranged from 16.5% to 10.2%. With increasing cutoff levels, sensitivity for early-stage CRCs and for screen-relevant neoplasia ranged from 84.2% to 78.9% and 47.1% to 37.2%, respectively.
CONCLUSIONS: Higher FIT cutoff levels substantially decrease test positivity rates with only limited effects on detection rates of early-stage CRCs. However, spectrum bias resulting in higher estimates of sensitivity than would be expected in a screening population may be present. IMPACT: Higher cutoff levels can reduce strain on colonoscopy capacity with only a modest decrease in sensitivity for curable cancers. ©2010 AACR.

Entities:  

Mesh:

Year:  2010        PMID: 21135261     DOI: 10.1158/1055-9965.EPI-10-0848

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  17 in total

Review 1.  Evaluation of the Effectiveness and Cost-Effectiveness of Personalized Surveillance After Colorectal Adenomatous Polypectomy.

Authors:  Ethna McFerran; James F O'Mahony; Richard Fallis; Duncan McVicar; Ann G Zauber; Frank Kee
Journal:  Epidemiol Rev       Date:  2017-01-01       Impact factor: 6.222

2.  Using the Cancer Risk Management Model to evaluate colorectal cancer screening options for Canada.

Authors:  A J Coldman; N Phillips; J Brisson; W Flanagan; M Wolfson; C Nadeau; N Fitzgerald; A B Miller
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

3.  Similar fecal immunochemical test results in screening and referral colorectal cancer.

Authors:  Sietze T van Turenhout; Leo G M van Rossum; Frank A Oort; Robert J F Laheij; Anne F van Rijn; Jochim S Terhaar sive Droste; Paul Fockens; René W M van der Hulst; Anneke A Bouman; Jan B M J Jansen; Gerrit A Meijer; Evelien Dekker; Chris J J Mulder
Journal:  World J Gastroenterol       Date:  2012-10-14       Impact factor: 5.742

4.  Evaluation of fecal immunochemical tests for colorectal cancer screening.

Authors:  Jeanette M Daly; Camden P Bay; Barcey T Levy
Journal:  J Prim Care Community Health       Date:  2013-05-12

5.  Faecal immunochemical testing (FIT) in patients with signs or symptoms of suspected colorectal cancer (CRC): a joint guideline from the Association of Coloproctology of Great Britain and Ireland (ACPGBI) and the British Society of Gastroenterology (BSG).

Authors:  Kevin J Monahan; Michael M Davies; Muti Abulafi; Ayan Banerjea; Brian D Nicholson; Ramesh Arasaradnam; Neil Barker; Sally Benton; Richard Booth; David Burling; Rachel Victoria Carten; Nigel D'Souza; James Edward East; Jos Kleijnen; Michael Machesney; Maria Pettman; Jenny Pipe; Lance Saker; Linda Sharp; James Stephenson; Robert Jc Steele
Journal:  Gut       Date:  2022-07-12       Impact factor: 31.793

6.  Use of a low cut-off value for the fecal immunochemical test enables better detection of proximal neoplasia.

Authors:  Jae Myung Cha; Joung Il Lee; Kwang Ro Joo; Hyun Phil Shin; Jung Won Jeun; Jun Uk Lim
Journal:  Dig Dis Sci       Date:  2013-08-04       Impact factor: 3.199

Review 7.  Fecal immunochemical tests in combination with blood tests for colorectal cancer and advanced adenoma detection-systematic review.

Authors:  Tobias Niedermaier; Korbinian Weigl; Michael Hoffmeister; Hermann Brenner
Journal:  United European Gastroenterol J       Date:  2017-10-09       Impact factor: 4.623

8.  Double sampling of a faecal immunochemical test is not superior to single sampling for detection of colorectal neoplasia: a colonoscopy controlled prospective cohort study.

Authors:  Frank A Oort; Sietze T van Turenhout; Veerle M H Coupé; René W M van der Hulst; Eric I C Wesdorp; Jochim S Terhaar sive Droste; Ilhame Ben Larbi; Shannon L Kanis; Edwin van Hengel; Anneke A Bouman; Gerrit A Meijer; Chris J J Mulder
Journal:  BMC Cancer       Date:  2011-10-10       Impact factor: 4.430

9.  Prospective cross-sectional study on faecal immunochemical tests: sex specific cut-off values to obtain equal sensitivity for colorectal cancer?

Authors:  Sietze T van Turenhout; Frank A Oort; René W M van der Hulst; Arjen P Visscher; Jochim S Terhaar sive Droste; Pieter Scholten; Anneke A Bouman; Gerrit A Meijer; Chris J J Mulder; Leo G M van Rossum; Veerle M H Coupé
Journal:  BMC Gastroenterol       Date:  2014-12-21       Impact factor: 3.067

Review 10.  Advances in Fecal Occult Blood Tests: the FIT revolution.

Authors:  Graeme P Young; Erin L Symonds; James E Allison; Stephen R Cole; Callum G Fraser; Stephen P Halloran; Ernst J Kuipers; Helen E Seaman
Journal:  Dig Dis Sci       Date:  2014-12-10       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.